Entry
Name
Prostate cancer - Homo sapiens (human)
Description
Prostate cancer constitutes a major health problem in Western countries. It is the most frequently diagnosed cancer among men and the second leading cause of male cancer deaths. The identification of key molecular alterations in prostate-cancer cells implicates carcinogen defenses (GSTP1), growth-factor-signaling pathways (NKX3.1, PTEN, and p27), and androgens (AR) as critical determinants of the phenotype of prostate-cancer cells. Glutathione S-transferases (GSTP1) are detoxifying enzymes. Cells of prostatic intraepithelial neoplasia, devoid of GSTP1, undergo genomic damage mediated by carcinogens. NKX3.1, PTEN, and p27 regulate the growth and survival of prostate cells in the normal prostate. Inadequate levels of PTEN and NKX3.1 lead to a reduction in p27 levels and to increased proliferation and decreased apoptosis. Androgen receptor (AR) is a transcription factor that is normally activated by its androgen ligand. During androgen withdrawal therapy, the AR signal transduction pathway also could be activated by amplification of the AR gene, by AR gene mutations, or by altered activity of AR coactivators. Through these mechanisms, tumor cells lead to the emergence of androgen-independent prostate cancer.
Class
Human Diseases; Cancer: specific types
BRITE hierarchy
Pathway map
Network
Element
N00052 Mutation-inactivated PTEN to PI3K signaling pathway
N00082 Loss of NKX3-1 to PI3K signaling pathway
N00084 Amplified AR to androgen receptor signaling pathway
N00085 Mutation-activated AR to androgen receptor signaling pathway
N00093 Loss of CDKN1B to p27-cell cycle G1/S
Disease
Drug
D00586 Flutamide (JP18/USP/INN)
D00961 Bicalutamide (JP18/USP/INN)
D01299 Chlormadinone acetate (JP18/USAN)
D03372 Capromab pendetide (USAN)
D04525 Indium In 111 capromab pendetide (USP)
D10070 Iofolastat I 123 (USAN)
D10218 Enzalutamide (JAN/USAN)
D11045 Darolutamide (JAN/USAN/INN)
D12132 Piflufolastat F-18 (USAN)
D12257 Gallium Ga 68 gozetotide (USAN)
D12335 Lutetium Lu 177 vipivotide tetraxetan (USAN)
D12606 Flotufolastat F18 gallium (USAN)
D13129 Abefolastat tesaroxetan (USAN/INN)
Organism
Homo sapiens (human) [GN:
hsa ]
Gene
1026 CDKN1A; cyclin dependent kinase inhibitor 1A [KO:K06625 ]
1027 CDKN1B; cyclin dependent kinase inhibitor 1B [KO:K06624 ]
10488 CREB3; cAMP responsive element binding protein 3 [KO:K09048 ]
113235 SLC46A1; solute carrier family 46 member 1 [KO:K14613 ]
1147 CHUK; component of inhibitor of nuclear factor kappa B kinase complex [KO:K04467 ] [EC:2.7.11.10 ]
1385 CREB1; cAMP responsive element binding protein 1 [KO:K05870 ]
148327 CREB3L4; cAMP responsive element binding protein 3 like 4 [KO:K09048 ]
2078 ERG; ETS transcription factor ERG [KO:K09435 ]
2119 ETV5; ETS variant transcription factor 5 [KO:K15593 ]
2885 GRB2; growth factor receptor bound protein 2 [KO:K04364 ]
2911 GRM1; glutamate metabotropic receptor 1 [KO:K04603 ]
2915 GRM5; glutamate metabotropic receptor 5 [KO:K04604 ]
2950 GSTP1; glutathione S-transferase pi 1 [KO:K23790 ]
3265 HRAS; HRas proto-oncogene, GTPase [KO:K02833 ]
3320 HSP90AA1; heat shock protein 90 alpha family class A member 1 [KO:K04079 ]
3326 HSP90AB1; heat shock protein 90 alpha family class B member 1 [KO:K04079 ]
3479 IGF1; insulin like growth factor 1 [KO:K05459 ]
3845 KRAS; KRAS proto-oncogene, GTPase [KO:K07827 ]
468 ATF4; activating transcription factor 4 [KO:K04374 ]
4790 NFKB1; nuclear factor kappa B subunit 1 [KO:K02580 ]
4893 NRAS; NRAS proto-oncogene, GTPase [KO:K07828 ]
51176 LEF1; lymphoid enhancer binding factor 1 [KO:K04492 ]
5154 PDGFA; platelet derived growth factor subunit A [KO:K04359 ]
5155 PDGFB; platelet derived growth factor subunit B [KO:K17386 ]
5290 PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [KO:K00922 ] [EC:2.7.1.153 ]
5291 PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta [KO:K00922 ] [EC:2.7.1.153 ]
5293 PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta [KO:K00922 ] [EC:2.7.1.153 ]
5295 PIK3R1; phosphoinositide-3-kinase regulatory subunit 1 [KO:K02649 ]
5296 PIK3R2; phosphoinositide-3-kinase regulatory subunit 2 [KO:K02649 ]
56034 PDGFC; platelet derived growth factor C [KO:K05450 ]
572 BAD; BCL2 associated agonist of cell death [KO:K02158 ]
5925 RB1; RB transcriptional corepressor 1 [KO:K06618 ]
596 BCL2; BCL2 apoptosis regulator [KO:K02161 ]
5970 RELA; RELA proto-oncogene, NF-kB subunit [KO:K04735 ]
64764 CREB3L2; cAMP responsive element binding protein 3 like 2 [KO:K09048 ]
6573 SLC19A1; solute carrier family 19 member 1 [KO:K14609 ]
6654 SOS1; SOS Ras/Rac guanine nucleotide exchange factor 1 [KO:K03099 ]
6655 SOS2; SOS Ras/Rho guanine nucleotide exchange factor 2 [KO:K03099 ]
6692 SPINT1; serine peptidase inhibitor, Kunitz type 1 [KO:K15619 ]
6934 TCF7L2; transcription factor 7 like 2 [KO:K04491 ]
6935 ZEB1; zinc finger E-box binding homeobox 1 [KO:K09299 ]
7039 TGFA; transforming growth factor alpha [KO:K08774 ]
7184 HSP90B1; heat shock protein 90 beta family member 1 [KO:K09487 ]
7850 IL1R2; interleukin 1 receptor type 2 [KO:K04387 ]
80310 PDGFD; platelet derived growth factor D [KO:K05450 ]
83439 TCF7L1; transcription factor 7 like 1 [KO:K04490 ]
84699 CREB3L3; cAMP responsive element binding protein 3 like 3 [KO:K09048 ]
8503 PIK3R3; phosphoinositide-3-kinase regulatory subunit 3 [KO:K02649 ]
8517 IKBKG; inhibitor of nuclear factor kappa B kinase regulatory subunit gamma [KO:K07210 ]
90993 CREB3L1; cAMP responsive element binding protein 3 like 1 [KO:K09048 ]
9586 CREB5; cAMP responsive element binding protein 5 [KO:K09047 ]
Compound
C05981 Phosphatidylinositol-3,4,5-trisphosphate
C12270 N-Acetylaspartylglutamate
C16038 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine
Reference
Authors
Nelson WG, De Marzo AM, Isaacs WB.
Title
Prostate cancer.
Journal
Reference
Authors
Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ, Wheeler TM, Miles BJ, Kadmon D, Thompson TC.
Title
The emerging role of the PI3-K-Akt pathway in prostate cancer progression.
Journal
Reference
Authors
Pienta KJ, Bradley D.
Title
Mechanisms underlying the development of androgen-independent prostate cancer.
Journal
Reference
Authors
Feldman BJ, Feldman D.
Title
The development of androgen-independent prostate cancer.
Journal
Reference
Authors
Heinlein CA, Chang C.
Title
Androgen receptor in prostate cancer.
Journal
Reference
Authors
Koivisto P, Kolmer M, Visakorpi T, Kallioniemi OP.
Title
Androgen receptor gene and hormonal therapy failure of prostate cancer.
Journal
Am J Pathol 152:1-9 (1998)
Reference
Authors
Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D.
Title
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor.
Journal
Reference
Authors
Macri E, Loda M.
Title
Role of p27 in prostate carcinogenesis.
Journal
Reference
Authors
Steers WD.
Title
5alpha-reductase activity in the prostate.
Journal
Reference
Authors
Lin D, Meyer DJ, Ketterer B, Lang NP, Kadlubar FF.
Title
Effects of human and rat glutathione S-transferases on the covalent DNA binding of the N-acetoxy derivatives of heterocyclic amine carcinogens in vitro: a possible mechanism of organ specificity in their carcinogenesis.
Journal
Cancer Res 54:4920-6 (1994)
Reference
Authors
Grimes CA, Jope RS.
Title
The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling.
Journal
Reference
Authors
Leshem O, Madar S, Kogan-Sakin I, Kamer I, Goldstein I, Brosh R, Cohen Y, Jacob-Hirsch J, Ehrlich M, Ben-Sasson S, Goldfinger N, Loewenthal R, Gazit E, Rotter V, Berger R
Title
TMPRSS2/ERG promotes epithelial to mesenchymal transition through the ZEB1/ZEB2 axis in a prostate cancer model.
Journal
Reference
Authors
Yu J, Yu J, Mani RS, Cao Q, Brenner CJ, Cao X, Wang X, Wu L, Li J, Hu M, Gong Y, Cheng H, Laxman B, Vellaichamy A, Shankar S, Li Y, Dhanasekaran SM, Morey R, Barrette T, Lonigro RJ, Tomlins SA, Varambally S, Qin ZS, Chinnaiyan AM
Title
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Journal
Reference
Authors
Squire JA
Title
TMPRSS2-ERG and PTEN loss in prostate cancer.
Journal
Reference
Authors
Adamo P, Ladomery MR
Title
The oncogene ERG: a key factor in prostate cancer.
Journal
Reference
Authors
Burdova A, Bouchal J, Tavandzis S, Kolar Z
Title
TMPRSS2-ERG gene fusion in prostate cancer.
Journal
Reference
Authors
Helgeson BE, Tomlins SA, Shah N, Laxman B, Cao Q, Prensner JR, Cao X, Singla N, Montie JE, Varambally S, Mehra R, Chinnaiyan AM
Title
Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Journal
Reference
Authors
Kim H, Datta A, Talwar S, Saleem SN, Mondal D, Abdel-Mageed AB
Title
Estradiol-ERbeta2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion.
Journal
Reference
Authors
Bakht MK, Beltran H
Title
Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.
Journal
Related pathway
hsa04060 Cytokine-cytokine receptor interaction
hsa04981 Folate transport and metabolism
hsa05202 Transcriptional misregulation in cancer
KO pathway